Peer-reviewed veterinary case report
Discovery of a class of potent gap-junction modifiers as novel antiarrhythmic agents.
- Journal:
- Bioorganic & medicinal chemistry letters
- Year:
- 2009
- Authors:
- Piatnitski Chekler, Eugene L et al.
- Affiliation:
- Wyeth Research · United States
Abstract
In an effort to discover potent, orally bioavailable compounds for the treatment of atrial fibrillation (AF) and ventricular tachycardia (VT), we developed a class of gap-junction modifiers typified by GAP-134 (1, R(1)=OH, R(2)=NH(2)), a compound currently under clinical evaluation. Selected compounds with the desired in-vitro profile demonstrated positive in vivo results in the mouse CaCl(2) arrhythmia model upon oral administration.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication: https://pubmed.ncbi.nlm.nih.gov/19616941/